Granted Patent B2

US 12,410,255 · App. 18/193,581 · Granted Sep 9, 2025

Inventors: John Louis Diener (Cambridge, MA); Lars Gadtke (Munich, DE); Felix Hartlepp (Munich, DE); Tiancen Hu (Woodbridge, CT); Kathrin Ladetzki-Baehs (Planegg, DE); Michael John Romanowski (Lexington, MA); Cesare Russo (Bachlettenstrasse, CH); Xenia Wezler (Munich, DE); Xiaoling Xie (Cambridge, MA)

Assignee: NOVARTIS AG

C07K16/2869C12N15/63A61K39/3955A61K2039/505A61K45/06A61P9/00A61P13/12C07K14/58C07K14/72C07K2317/50C07K2317/54C07K2317/55C07K2317/56C07K2317/565C07K2317/622C07K2317/75

Abstract

Claims (44)

1. An isolated nucleic acid or nucleic acids encoding the amino acid sequence of an anti-NPR1 antibody or antigen binding fragment, wherein the antibody or antigen binding fragment comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) and three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3) selected from:

(I) 

SEQ ID NO: 28 (HCDR1),  

SEQ ID NO: 119 (HCDR2),

SEQ ID NO: 30 (HCDR3),  

SEQ ID NO: 41 (LCDR1), 

SEQ ID NO: 42 (LCDR2), and

SEQ ID NO: 134 (LCDR3);

(II) 

SEQ ID NO: 31 (HCDR1),  

SEQ ID NO: 119 (HCDR2), 

SEQ ID NO: 30 (HCDR3),

SEQ ID NO: 41 (LCDR1), 

SEQ ID NO: 42 (LCDR2), and 

SEQ ID NO: 134 (LCDR3);

(III)  

SEQ ID NO: 32 (HCDR1),

SEQ ID NO: 120 (HCDR2), 

SEQ ID NO: 30 (HCDR3), 

SEQ ID NO: 44 (LCDR1), 

SEQ ID NO: 45 (LCDR2), and 

SEQ ID NO: 135 (LCDR3); or

(IV) 

SEQ ID NO: 34 (HCDR1), 

SEQ ID NO: 121 (HCDR2), 

SEQ ID NO: 36 (HCDR3), 

SEQ ID NO: 47 (LCDR1), 

SEQ ID NO: 45 (LCDR2), and 

SEQ ID NO: 134 (LCDR3).

2. A vector comprising the isolated nucleic acid(s) of claim 1 .

3. A host cell comprising the isolated nucleic acid(s) of claim 1 .

4. A method of producing an isolated anti-NPR1 antibody or antigen binding fragment, comprising culturing the host cell of claim 3 under conditions suitable for producing the antibody or antigen binding fragment.

5. The isolated nucleic acid(s) of claim 1 , wherein the antibody or antigen binding fragment comprises:

(a) a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 201, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 136; or

(b) a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 122, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 136.

6. A vector comprising the isolated nucleic acid(s) of claim 5 .

7. A host cell comprising the isolated nucleic acid(s) of claim 5 .

8. A method of producing an isolated anti-NPR1 antibody or antigen binding fragment, comprising culturing the host cell of claim 7 under conditions suitable for producing the antibody or antigen binding fragment.

9. The isolated nucleic acid(s) of claim 1 , wherein the antibody or antigen binding fragment comprises:

(a) a heavy chain comprising an amino acid sequence of SEQ ID NO: 203, and a light chain comprising an amino acid sequence of SEQ ID NO: 138; or

(b) a heavy chain comprising an amino acid sequence of SEQ ID NO: 208, and a light chain comprising an amino acid sequence of SEQ ID NO: 138.

10. A vector comprising the isolated nucleic acid(s) of claim 9 .

11. A host cell comprising the isolated nucleic acid(s) of claim 9 .

12. A method of producing an isolated anti-NPR1 antibody or antigen binding fragment, comprising culturing the host cell of claim 11 under conditions suitable for producing the antibody or antigen binding fragment.

Assignments (4)

Continuity (4)

References Cited (76)